MetaCap

Biogen Inc. (BIIB)

NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

249.59+2.46 (+1.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BIIB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$36.89B
P/E (TTM)
108.05
52-week range
160.36 – 261.00
Day range
248.04 – 253.00
Volume / Avg
1.13M / 1.10M
Beta
—

52-week range

$160.36$261.00

BIIB stock today

On Nov 20, BIIB ended the session at $249.59, adding $2.46 (1.00%), versus the S&P 500's 3.70% decline. At this level, BIIB sits near the top of its 52-week range of $160.36 to $261.00: 4.4% below the high, set on Nov 9, 2026 and 55.6% above the low. BIIB is up 41.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 42.4%.

At 108.0x trailing earnings, Biogen trades above the peer-group median of 22.8x. Its forward P/E of 15.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Biogen

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Christopher A. Viehbacher
Headquarters
Cambridge, MA
Employees
7,500
Website
biogen.com

Financial highlights

Full financials

In fiscal 2025, Biogen generated $9.89 billion in revenue, up 2.2% from fiscal 2024. Net income was $1.29 billion (-20.8% year over year), for a net margin of 13.1% versus a median of 16.9% in the prior 5 years. Gross margin was 75.7% (down from 76.1%).

Biogen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$9.89B$9.68B$9.84B$10.17B$10.98B
Growth+2.22%-1.62%-3.32%-7.36%-18.32%
Net income$1.29B$1.63B$1.16B$3.05B$1.56B
EPS (diluted)$8.79$11.18$7.97$20.87$10.40

Analyst forecast

Forecast

Consensus (36 analysts)

buy

Avg. price target

$268.26+7.48%

  • Strong buy 4
  • Buy 21
  • Hold 10
  • Sell 1
  • Strong sell 0

Target range

Low $175.00High $350.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.14 vs $2.06
Surprise
-106.80%

BIIB news

All BIIB news

Biogen peers

Health Care sector
BIIB peer companies
CompanyPrice% ChgMarket capCompare
RVMDRevolution Medicines Inc.161.20+1.11%$34.87Bvs BIIB
BNTXBioNTech SE ADR80.96-0.52%$20.07Bvs BIIB
EXELExelixis Inc.64.63-1.82%$15.77Bvs BIIB
NBIXNeurocrine Biosciences Inc.150.57-3.84%$15.24Bvs BIIB
ARGXargenx SE ADR925.70-1.73%$58.21Bvs BIIB
TECHBio-Techne Corp72.67-0.04%$11.42Bvs BIIB
RGENRepligen Corporation163.81-3.81%$10.47Bvs BIIB
HALOHalozyme Therapeutics Inc.91.35-1.82%$10.41Bvs BIIB

Indexes, lists and sector

Biogen stock FAQ

What is Biogen's stock price today?

BIIB last traded at $249.59 as of Nov 20, 4:00 PM EST, up 1.00% on the day. Prices are delayed at least 15 minutes.

Does Biogen pay a dividend?

No. Biogen does not currently pay a regular cash dividend.

What is BIIB's P/E ratio?

BIIB trades at a trailing P/E ratio of 108.05 and a forward P/E of 15.37, compared with a median of 22.8 for its closest peers.

Is Biogen in the S&P 500?

Yes. Biogen (BIIB) is a constituent of the S&P 500 index.

Who is Biogen's CEO?

Mr. Christopher A. Viehbacher is the chief executive officer of Biogen Inc., which has about 7,500 employees.

Has BIIB ever split its stock?

Yes. The most recent BIIB stock split was a 3-for-1 split on Jan 18, 2001, one of 2 splits on record.

What is the BIIB 52-week high?

The 52-week high for BIIB is $261.00 and the 52-week low is $160.36. The stock is currently 4.4% below its high.

Compare BIIB